402 related articles for article (PubMed ID: 15637527)
1. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
[TBL] [Abstract][Full Text] [Related]
2. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
[TBL] [Abstract][Full Text] [Related]
3. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
[TBL] [Abstract][Full Text] [Related]
5. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
Dresser GK; Kim RB; Bailey DG
Clin Pharmacol Ther; 2005 Mar; 77(3):170-7. PubMed ID: 15735611
[TBL] [Abstract][Full Text] [Related]
6. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment.
Olsén L; Ingvast-Larsson C; Larsson P; Broström H; Bondesson U; Sundqvist M; Tjälve H
J Vet Pharmacol Ther; 2006 Apr; 29(2):129-35. PubMed ID: 16515667
[TBL] [Abstract][Full Text] [Related]
7. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
[TBL] [Abstract][Full Text] [Related]
8. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
[TBL] [Abstract][Full Text] [Related]
9. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Uno T; Shimizu M; Sugawara K; Tateishi T
Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
[TBL] [Abstract][Full Text] [Related]
10. The effect of rifampin administration on the disposition of fexofenadine.
Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
[TBL] [Abstract][Full Text] [Related]
11. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H
Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
[TBL] [Abstract][Full Text] [Related]
12. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S
Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of fexofenadine enantiomers.
Miura M; Uno T
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):69-74. PubMed ID: 19947891
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
15. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model.
Petri N; Bergman E; Forsell P; Hedeland M; Bondesson U; Knutson L; Lennernäs H
Drug Metab Dispos; 2006 Jul; 34(7):1182-9. PubMed ID: 16621934
[TBL] [Abstract][Full Text] [Related]
16. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
Shimizu M; Uno T; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
[TBL] [Abstract][Full Text] [Related]
17. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.
Bailey DG; Dresser GK; Leake BF; Kim RB
Clin Pharmacol Ther; 2007 Apr; 81(4):495-502. PubMed ID: 17301733
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
Miura M; Uno T; Tateishi T; Suzuki T
Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.
Tahara H; Kusuhara H; Maeda K; Koepsell H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2006 May; 34(5):743-7. PubMed ID: 16455804
[TBL] [Abstract][Full Text] [Related]
20. Effect of St John's wort on the pharmacokinetics of fexofenadine.
Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
